Novartis AG (NVS)
160.50
+0.25
(+0.16%)
USD |
NYSE |
Nov 13, 16:00
161.39
+0.89
(+0.55%)
Pre-Market: 06:14
Novartis Enterprise Value : 342.80B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 342.80B |
| November 12, 2026 | 342.32B |
| November 11, 2026 | 342.46B |
| November 10, 2026 | 348.01B |
| November 09, 2026 | 348.82B |
| November 06, 2026 | 346.67B |
| November 05, 2026 | 345.50B |
| November 04, 2026 | 351.26B |
| November 03, 2026 | 340.45B |
| November 02, 2026 | 344.72B |
| October 30, 2026 | 343.34B |
| October 29, 2026 | 343.93B |
| October 28, 2026 | 334.45B |
| October 27, 2026 | 335.92B |
| October 26, 2026 | 330.16B |
| October 23, 2026 | 325.08B |
| October 22, 2026 | 334.81B |
| October 21, 2026 | 330.39B |
| October 20, 2026 | 329.84B |
| October 19, 2026 | 323.34B |
| October 16, 2026 | 324.14B |
| October 15, 2026 | 323.68B |
| October 14, 2026 | 317.07B |
| October 13, 2026 | 308.63B |
| October 12, 2026 | 311.33B |
| Date | Value |
|---|---|
| October 09, 2026 | 311.16B |
| October 08, 2026 | 309.95B |
| October 07, 2026 | 310.27B |
| October 06, 2026 | 305.57B |
| October 05, 2026 | 305.83B |
| October 02, 2026 | 305.97B |
| October 01, 2026 | 306.06B |
| September 30, 2026 | 308.93B |
| September 29, 2026 | 308.46B |
| September 28, 2026 | 310.60B |
| September 25, 2026 | 308.00B |
| September 24, 2026 | 304.54B |
| September 23, 2026 | 302.97B |
| September 22, 2026 | 300.35B |
| September 21, 2026 | 299.80B |
| September 18, 2026 | 298.68B |
| September 17, 2026 | 299.69B |
| September 16, 2026 | 295.63B |
| September 15, 2026 | 295.48B |
| September 14, 2026 | 296.16B |
| September 11, 2026 | 292.81B |
| September 10, 2026 | 293.39B |
| September 09, 2026 | 293.39B |
| September 08, 2026 | 293.79B |
| September 04, 2026 | 334.60B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 598.40B |
| GSK Plc | 128.16B |
| Johnson & Johnson | 715.26B |
| Eli Lilly & Co. | 1.403T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.189B |
| Revenue (Quarterly) | 14.44B |
| Total Expenses (Quarterly) | 13.24B |
| EPS Diluted (Quarterly) | 0.6272 |
| Gross Profit Margin (Quarterly) | 75.40% |
| Profit Margin (Quarterly) | 8.24% |
| Earnings Yield | 3.26% |
| Operating Earnings Yield | 5.48% |
| Normalized Earnings Yield | 4.098 |